Global Blood Grouping Reagents Market Grows Steadily at a CAGR of 9.01%

Introduction

Blood grouping reagents are substances used to identify human blood group antigens (like ABO, Rhesus, Kell, and MNS blood group antigens). The most important blood group systems for transfusions are ABO and RhD. Blood groups are distinguished on the surface of human red cells by a carbohydrate molecule (such as the ABO blood group antigens) or a protein molecule (such as most other antigens).

The ABO system includes antigens A and B, while the RhD system includes antigens D. The ABO blood group is identified with Anti-A, Anti-B, and Anti-A, B reagents. In contrast, anti-D reagents are utilized to determine the rhesus D phenotype. Anti-K and Anti-K (Cellano) reagents detect antigens belonging to the Kell blood group system.

Market Dynamics 

Growing Prevalence of Chronic Disorders Market Drives the Global Market

The increasing prevalence of chronic disorders necessitates the development of effective treatments. Chronic diseases like anemia, hemophilia, lymphoma, diabetes, and leukemia represent a substantial burden in addition to the ongoing COVID-19 pandemic. According to the Centers for Disease Control and Prevention, in 2019, six out of ten adults suffered from chronic disease, with four out of ten adults suffering from more than two chronic illnesses.

In addition, the WHO estimates that anemia affects approximately 24.8% of the world's population or approximately 1.62 billion individuals. Thus, the rising prevalence of chronic diseases, particularly those associated with blood, is anticipated to stimulate market expansion over the forecast period.

Advent of Automated Blood Grouping Devices Creates Tremendous Opportunities

Population growth and increased blood grouping diagnostics have generated a demand for automated blood grouping devices. The automated systems can conduct numerous evaluations with a single input, increasing productivity and efficiency within the allotted time frame. These devices are programmed to conduct high-precision and consistency tests while preventing sample contamination.

Additionally, market participants provide entirely automated blood grouping devices with remote access capabilities for enhanced monitoring and result validation. This equipment has features such as tube size and diameter recognition, an integrated quality control program, random sample placement, real-time reagent and sample status information, and high-definition color results. Therefore, the advantages of automated blood grouping devices will present market expansion opportunities.

Regional Analysis

North America is the most significant global blood grouping reagents market shareholder and is expected to expand substantially over the forecast period. The prevalence of blood grouping reagents in North America is rising due to various factors. In the upcoming years, there will likely be a growth in North America's blood grouping reagent market due to the aging population, rising incidence of chronic illnesses, and an increase in surgical operations. This necessitates using blood grouping reagents to accurately group and cross-match blood. There is also a correlation between the increasing demand for blood grouping reagents and the rising need for blood transfusions throughout the region. Givingblood.org estimates that by 2023, 4.5 million Americans will need blood transfusions annually.

In addition, collaborations and partnerships between blood banks, healthcare providers, and manufacturers of blood classification reagents have emerged in North America. These collaborations seek to advance the development, adoption, and research of state-of-the-art blood grouping reagents to hasten market expansion. For instance, Bio-Rad Laboratories announced a partnership with Seegene in 2021 to manufacture and market molecular diagnostic instruments for infectious diseases.

Key Highlights

• The global blood grouping reagents market was valued at USD 1.95 billion in 2022. It is estimated to reach USD 3.88 billion by 2031, growing at a CAGR of 9.01% during the forecast period (2023–2031).
• Based on product, the global blood grouping reagents market is segmented into consumables and instruments. The consumables segment is the most significant revenue contributor to the market.
• Based on technology, the global blood grouping reagents market is bifurcated into PCR-based and microarray techniques, assay-based techniques, massively parallel sequencing techniques, serology, and other techniques. The PCR-based and microarray technique segment is the highest contributor to the market.
• Based on test type, the global blood grouping reagents market is bifurcated into blood group and phenotype, antibody screening, cross-matching tests, antibody identification, Coombs tests, and antigen typing. The antibody screening segment dominates the global market.
• Based on end-users, the global blood grouping reagents market is bifurcated into hospitals and blood banks, clinical laboratories, and academic and research institutes. The hospitals and blood banks segment owns the market share.
• North America is the most significant global blood grouping reagents market shareholder and is expected to expand substantially over the forecast period.

Competitive Players

1. Merck KGaA
2. Bio-Rad Laboratories, Inc
3. Novacyt Group
4. Beckman Coulter, Inc
5. Haemokinesis Pty Ltd
6. Rapid Labs Ltd
7. Cardinal Health
8. Thermo Fisher Scientific Inc.
9. Diagast
10. Atlas Medical
11. Alba Bioscience Limited
12. PerkinElmer
13. Lorne Laboratories Limited
14. BAG Diagnostics
15. Biorex Diagnostic

Recent Developments

• July 2023- Quanterix Corporation, a business fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, announced the launch of LucentAD, a test designed to aid in evaluating patients exhibiting cognitive symptoms consistent with the early stages of Alzheimer's disease (AD).
• August 2023- C2N Diagnostics introduced a new blood test called PrecivityAD2 for clinical use. The new blood test can diagnose Alzheimer's disease (AD) and other causes of cognitive decline in patients with Alzheimer's disease (AD) symptoms.

Segmentation

1. By Product
   1. Consumables
   2. Instruments
   3. Service And Software
2. By Technique
   1. PCR-based and Microarray Technique
   2. Assay-Based Techniques
   3. Massively Parallel Sequencing Techniques
   4. Serology
   5. Other Techniques
3. By Test Type
   1. Blood Group and Phenotype
   2. Antibody Screening
   3. Cross-matching Tests
   4. Antibody Identification
   5. Coombs Tests
   6. Antigen Typing
4. By End-User
   1. Hospitals and Blood Banks
   2. Clinical Laboratories
   3. Academic and Research Institutes